TORONTO, Sept. 4, 2012 /CNW/ - China Health Labs & Diagnostics Ltd.
("China Health" or the "Company") (TSXV:CHO); (OTCQX:CHLBF) announced
today that the term of its contract for investor relations service with
Langda Consulting ("Langda") ended August 31, 2012 and the Company will
not be renewing this contract. Langda provided strategic investor
relations services to the Company since September 2011 that focused on
communities and investors that have an interest in China-based
"I would like to express my appreciation to Langda and its principals
for their service and dedication provided to the Company," said Mr.
Shiping (Wilson) Yao, President and CEO of China Health.
About China Health Labs & Diagnostics Ltd.
China Health, operating in China as the Biochem Group, is a leading
diagnostic lab solution provider for the public healthcare industry in
China. The Company develops and sells Biochem Group branded and
third-party medical diagnostic products and services to diagnostic
facilities in China. Customers include large urban hospitals, rural
hospitals, Chinese military and rescue operations, the Beijing
government and third-party distributors.
In 2011, China Health had revenue of approximately $45.6 million, and
intends to expand its business by focusing its efforts on expanding its
sales network in three areas where it provides proprietary solutions,
has limited competition and that are supported by Chinese government
policy and budgets: BK Clinlab total lab solutions for rural hospitals
and clinics, POCT solutions for military and emergency rescue services,
and food safety solutions for large cities in China.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
FORWARD LOOKING INFORMATION
This press release contains forward-looking statements and information
that are based on the beliefs of management and reflect China Health's
current expectations. When used in this press release, the words
"estimate", "project", "belief", "anticipate", "intend", "expect",
"plan", "predict", "may" or "should" and the negative of these words or
such variations thereon or comparable terminology are intended to
identify forward-looking statements and information. The
forward-looking statements and information in this press release
includes information relating to the expansion of the Company's
business through its sales network in areas where it has proprietary
products, limited competition and strong government support. The
forward-looking information is based on certain assumptions, which
could change materially in the future, including the assumption that
the Company will be able to expand its sales network and business.
Such statements and information reflect the current view of China
Health with respect to risks and uncertainties that may cause actual
results to differ materially from those contemplated in those
forward-looking statements and information. By their nature,
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements, or other future events, to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Such factors
include, among others, the risk that the Company may not be able to
expand its business as expected through its sales network in any of the
areas in which it has proprietary products, limited competition and
strong government support. China Health cautions that the foregoing
list of material factors is not exhaustive. When relying on China
Health's forward-looking statements and information to make decisions,
investors and others should carefully consider the foregoing factors
and other uncertainties and potential events. China Health has assumed
a certain progression, which may not be realized. It has also assumed
that the material factors referred to above will not cause such
forward-looking statements and information to differ materially from
actual results or events. However, the list of these factors is not
exhaustive and is subject to change and there can be no assurance that
such assumptions will reflect the actual outcome of such items or
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE
REPRESENTS THE EXPECTATIONS OF CHINA HEALTH AS OF THE DATE OF THIS
PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE.
READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD-LOOKING
INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER
DATE. WHILE CHINA HEALTH MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE
THIS INFORMATION AT ANY PARTICULAR TIME EXCEPT AS REQUIRED IN
ACCORDANCE WITH APPLICABLE LAWS.
SOURCE: CHINA HEALTH LABS & DIAGNOSTICS
For further information:
Chief Financial Officer
China Health Labs & Diagnostics Ltd.
T: (416) 865-3351
TMX Equicom Group
T: (416) 815-0700 ext. 264